SENSUS HEALTHCARE INC (SRTS)
US81728J1097 - Common Stock
SRTS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 193 industry peers in the Health Care Equipment & Supplies industry. While SRTS has a great health rating, there are worries on its profitability. SRTS does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year SRTS was profitable.
In the past year SRTS has reported a negative cash flow from operations.
In multiple years SRTS reported negative net income over the last 5 years.
In the past 5 years SRTS always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.91%, SRTS is in the better half of the industry, outperforming 73.44% of the companies in the same industry.
The Return On Equity of SRTS (1.00%) is better than 72.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.91% | ||
| ROE | 1% | ||
| ROIC | N/A |
ROA(3y)18.8%
ROA(5y)5.48%
ROE(3y)22.42%
ROE(5y)5.87%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SRTS's Profit Margin of 2.01% is fine compared to the rest of the industry. SRTS outperforms 72.92% of its industry peers.
SRTS's Gross Margin of 57.61% is in line compared to the rest of the industry. SRTS outperforms 54.69% of its industry peers.
SRTS's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 2.01% | ||
| GM | 57.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.68%
GM growth 5Y-2.08%
2. Health
2.1 Basic Checks
SRTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SRTS remains at a similar level compared to 1 year ago.
Compared to 5 years ago, SRTS has more shares outstanding
SRTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 8.99 indicates that SRTS is not in any danger for bankruptcy at the moment.
SRTS has a better Altman-Z score (8.99) than 86.98% of its industry peers.
SRTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.99 |
ROIC/WACCN/A
WACC9.97%
2.3 Liquidity
SRTS has a Current Ratio of 11.76. This indicates that SRTS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 11.76, SRTS belongs to the top of the industry, outperforming 94.79% of the companies in the same industry.
A Quick Ratio of 8.23 indicates that SRTS has no problem at all paying its short term obligations.
SRTS has a Quick ratio of 8.23. This is amongst the best in the industry. SRTS outperforms 90.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.76 | ||
| Quick Ratio | 8.23 |
3. Growth
3.1 Past
The earnings per share for SRTS have decreased strongly by -95.59% in the last year.
Looking at the last year, SRTS shows a very negative growth in Revenue. The Revenue has decreased by -45.19% in the last year.
Measured over the past years, SRTS shows a decrease in Revenue. The Revenue has been decreasing by -1.58% on average per year.
EPS 1Y (TTM)-95.59%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q52.94%
Revenue 1Y (TTM)-45.19%
Revenue growth 3Y36.58%
Revenue growth 5Y-1.58%
Revenue growth Q2Q-4.07%
3.2 Future
SRTS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 130.46% yearly.
The Revenue is expected to grow by 19.31% on average over the next years. This is quite good.
EPS Next Y53%
EPS Next 2Y160.77%
EPS Next 3Y130.46%
EPS Next 5YN/A
Revenue Next Year14.82%
Revenue Next 2Y18.68%
Revenue Next 3Y19.31%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
SRTS is valuated quite expensively with a Price/Earnings ratio of 121.67.
Compared to the rest of the industry, the Price/Earnings ratio of SRTS indicates a somewhat cheap valuation: SRTS is cheaper than 67.19% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.73, SRTS is valued quite expensively.
A Price/Forward Earnings ratio of 79.52 indicates a quite expensive valuation of SRTS.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SRTS indicates a somewhat cheap valuation: SRTS is cheaper than 69.79% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.41, SRTS is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 121.67 | ||
| Fwd PE | 79.52 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as SRTS's earnings are expected to grow with 130.46% in the coming years.
PEG (NY)2.3
PEG (5Y)N/A
EPS Next 2Y160.77%
EPS Next 3Y130.46%
5. Dividend
5.1 Amount
SRTS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SENSUS HEALTHCARE INC
NASDAQ:SRTS (5/3/2024, 7:19:44 PM)
After market: 3.72 +0.07 (+1.92%)3.65
-0.21 (-5.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap59.82M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 121.67 | ||
| Fwd PE | 79.52 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)2.3
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.91% | ||
| ROE | 1% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | 2.01% | ||
| GM | 57.61% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 11.76 | ||
| Quick Ratio | 8.23 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-95.59%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y53%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-45.19%
Revenue growth 3Y36.58%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y